Lipovation
Specializing in Lipid-based Nano/micro Particle Medicines
Company Overview
Snapshot
Founded in February 2021, Lipovation operated with 1–10 employees, specializing in lipid-based nano/micro particle medicines. The company was acquired by Revium Rx in February 2025.
Business overview
Lipovation develops lipid-based nano/micro particle medicines, leveraging core technology conceptualized by Prof. Yehezkel Barenholz, the inventor of Doxil. The company's focus is on advancing drug delivery systems within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development.
Strategic signal
In February 2025, Revium Rx completed its acquisition of Lipovation Ltd. This acquisition signifies a strategic consolidation within the pharmaceutical and biotechnology landscape, indicating Revium Rx's intent to integrate Lipovation's specialized lipid-based nano/micro particle medicine technology into its portfolio. For investors, this signals a successful exit for Lipovation and a potential expansion of Revium Rx's drug development capabilities.
Log in to access full profile ›Company Intelligence Q&A
- What was a significant recent corporate development for Lipovation?
- In February 2025, Lipovation was acquired by Revium Rx, marking a key exit for the company.
- Who founded Lipovation?
- Lipovation's core technology was conceptualized by Prof. Yehezkel Barenholz, the inventor of Doxil.
- What is Lipovation's primary focus in the healthcare sector?
- Lipovation specializes in the development of lipid-based nano/micro particle medicines, operating within the Pharma & Medical Biotechnology and Drugs Discovery & Development sub-sectors.
- When was Lipovation founded?
- Lipovation was founded in February 2021.
- What is the status of Lipovation following the acquisition?
- Lipovation is currently inactive, having been acquired by Revium Rx in February 2025.